216 related articles for article (PubMed ID: 24702187)
1. Cerebrospinal fluid asparagine depletion during pegylated asparaginase therapy in children with acute lymphoblastic leukaemia.
Henriksen LT; Nersting J; Raja RA; Frandsen TL; Rosthøj S; Schrøder H; Albertsen BK;
Br J Haematol; 2014 Jul; 166(2):213-20. PubMed ID: 24702187
[TBL] [Abstract][Full Text] [Related]
2. Cerebrospinal fluid asparagine concentrations after Escherichia coli asparaginase in children with acute lymphoblastic leukemia.
Woo MH; Hak LJ; Storm MC; Gajjar AJ; Sandlund JT; Harrison PL; Wang B; Pui CH; Relling MV
J Clin Oncol; 1999 May; 17(5):1568-73. PubMed ID: 10334545
[TBL] [Abstract][Full Text] [Related]
3. Levels of L-asparagine in CSF after intramuscular administration of asparaginase from Erwinia in children with acute lymphoblastic leukemia.
Dibenedetto SP; Di Cataldo A; Ragusa R; Meli C; Lo Nigro L
J Clin Oncol; 1995 Feb; 13(2):339-44. PubMed ID: 7844595
[TBL] [Abstract][Full Text] [Related]
4. Dose reduction of asparaginase under pharmacokinetic and pharmacodynamic control during induction therapy in children with acute lymphoblastic leukaemia.
Ahlke E; Nowak-Göttl U; Schulze-Westhoff P; Werber G; Börste H; Würthwein G; Jürgens H; Boos J
Br J Haematol; 1997 Mar; 96(4):675-81. PubMed ID: 9074406
[TBL] [Abstract][Full Text] [Related]
5. L-asparaginase pharmacokinetics and asparagine levels in cerebrospinal fluid of rhesus monkeys and humans.
Riccardi R; Holcenberg JS; Glaubiger DL; Wood JH; Poplack DG
Cancer Res; 1981 Nov; 41(11 Pt 1):4554-8. PubMed ID: 6895481
[TBL] [Abstract][Full Text] [Related]
6. Pegylated asparaginase (Oncaspar) in children with ALL: drug monitoring in reinduction according to the ALL/NHL-BFM 95 protocols.
Müller HJ; Löning L; Horn A; Schwabe D; Gunkel M; Schrappe M; von Schütz V; Henze G; Casimiro da Palma J; Ritter J; Pinheiro JP; Winkelhorst M; Boos J
Br J Haematol; 2000 Aug; 110(2):379-84. PubMed ID: 10971395
[TBL] [Abstract][Full Text] [Related]
7. L-asparagine depletion and L-asparaginase activity in children with acute lymphoblastic leukemia receiving i.m. or i.v. Erwinia C. or E. coli L-asparaginase as first exposure.
Rizzari C; Zucchetti M; Conter V; Diomede L; Bruno A; Gavazzi L; Paganini M; Sparano P; Lo Nigro L; Aricò M; Milani M; D'Incalci M
Ann Oncol; 2000 Feb; 11(2):189-93. PubMed ID: 10761754
[TBL] [Abstract][Full Text] [Related]
8. A fluorometric assay for L-asparaginase activity and monitoring of L-asparaginase therapy.
Ylikangas P; Mononen I
Anal Biochem; 2000 Apr; 280(1):42-5. PubMed ID: 10805519
[TBL] [Abstract][Full Text] [Related]
9. L-Asparagine depletion in plasma and cerebro-spinal fluid of children with acute lymphoblastic leukemia during subsequent exposures to Erwinia L-asparaginase.
Gentili D; Conter V; Rizzari C; Tschuemperlin B; Zucchetti M; Orlandoni D; D'Incalci M; Masera G
Ann Oncol; 1996 Sep; 7(7):725-30. PubMed ID: 8905031
[TBL] [Abstract][Full Text] [Related]
10. Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations.
Boos J; Werber G; Ahlke E; Schulze-Westhoff P; Nowak-Göttl U; Würthwein G; Verspohl EJ; Ritter J; Jürgens H
Eur J Cancer; 1996 Aug; 32A(9):1544-50. PubMed ID: 8911116
[TBL] [Abstract][Full Text] [Related]
11. Use of L-asparaginase in childhood ALL.
Müller HJ; Boos J
Crit Rev Oncol Hematol; 1998 Aug; 28(2):97-113. PubMed ID: 9768345
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and drug monitoring of L-asparaginase treatment.
Boos J
Int J Clin Pharmacol Ther; 1997 Mar; 35(3):96-8. PubMed ID: 9088996
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of PEG-L-asparaginase and plasma and cerebrospinal fluid L-asparagine concentrations in the rhesus monkey.
Berg SL; Balis FM; McCully CL; Godwin KS; Poplack DG
Cancer Chemother Pharmacol; 1993; 32(4):310-4. PubMed ID: 8324873
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Children's Oncology Group Study AALL07P4.
Angiolillo AL; Schore RJ; Devidas M; Borowitz MJ; Carroll AJ; Gastier-Foster JM; Heerema NA; Keilani T; Lane AR; Loh ML; Reaman GH; Adamson PC; Wood B; Wood C; Zheng HW; Raetz EA; Winick NJ; Carroll WL; Hunger SP
J Clin Oncol; 2014 Dec; 32(34):3874-82. PubMed ID: 25348002
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic dose adjustment of Erwinia asparaginase in protocol II of the paediatric ALL/NHL-BFM treatment protocols.
Vieira Pinheiro JP; Ahlke E; Nowak-Göttl U; Hempel G; Müller HJ; Lümkemann K; Schrappe M; Rath B; Fleischhack G; Mann G; Boos J
Br J Haematol; 1999 Feb; 104(2):313-20. PubMed ID: 10050714
[TBL] [Abstract][Full Text] [Related]
16. The three asparaginases. Comparative pharmacology and optimal use in childhood leukemia.
Asselin BL
Adv Exp Med Biol; 1999; 457():621-9. PubMed ID: 10500842
[TBL] [Abstract][Full Text] [Related]
17. Determination of L-asparagine in biological samples in the presence of L-asparaginase.
Gentili D; Zucchetti M; Conter V; Masera G; D'Incalci M
J Chromatogr B Biomed Appl; 1994 Jul; 657(1):47-52. PubMed ID: 7952083
[TBL] [Abstract][Full Text] [Related]
18. Changes in coagulation and fibrinolysis in childhood acute lymphoblastic leukaemia re-induction therapy using three different asparaginase preparations.
Nowak-Göttl U; Ahlke E; Klösel K; Jürgens H; Boos J
Eur J Pediatr; 1997 Nov; 156(11):848-50. PubMed ID: 9392397
[TBL] [Abstract][Full Text] [Related]
19. Asparagine synthetase activity in paediatric acute leukaemias: AML-M5 subtype shows lowest activity.
Dübbers A; Würthwein G; Müller HJ; Schulze-Westhoff P; Winkelhorst M; Kurzknabe E; Lanvers C; Pieters R; Kaspers GJ; Creutzig U; Ritter J; Boos J
Br J Haematol; 2000 May; 109(2):427-9. PubMed ID: 10848836
[TBL] [Abstract][Full Text] [Related]
20. Monitoring of asparagine depletion and anti-L-asparaginase antibodies in adult acute lymphoblastic leukemia treated in the pediatric-inspired GRAALL-2005 trial.
Paillassa J; Leguay T; Thomas X; Huguet F; Audrain M; Lheritier V; Vianey-Saban C; Acquaviva-Bourdain C; Pagan C; Dombret H; Ifrah N; Boissel N; Hunault-Berger M
Blood Cancer J; 2018 May; 8(5):45. PubMed ID: 29795175
[No Abstract] [Full Text] [Related]
[Next] [New Search]